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Eight years after an international workshop
on myotonic dystrophy patient registries:
case study of a global collaboration for a
rare disease
Libby Wood1*, Guillaume Bassez2, Corinne Bleyenheuft3, Craig Campbell4, Louise Cossette5,
Aura Cecilia Jimenez-Moreno1, Yi Dai6, Hugh Dawkins7, Jorge Alberto Diaz Manera8, Celine Dogan2,
Rasha el Sherif9, Barbara Fossati10, Caroline Graham7, James Hilbert11, Kristinia Kastreva12, En Kimura13,
Lawrence Korngut14, Anna Kostera-Pruszczyk15, Christopher Lindberg16, Bjorn Lindvall16, Elizabeth Luebbe11,
Anna Lusakowska15, Radim Mazanec17, Giovani Meola10, Liannna Orlando18, Masanori P. Takahashi19, Stojan Peric20,
Jack Puymirat5, Vidosava Rakocevic-Stojanovic20, Miriam Rodrigues21, Richard Roxburgh21, Benedikt Schoser22,
Sonia Segovia23, Andriy Shatillo24, Simone Thiele22, Ivailo Tournev12, Baziel van Engelen25, Stanislav Vohanka26
and Hanns Lochmüller27,28

Abstract
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated
10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are
currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with
the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of
key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after
this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the
proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy
patients worldwide (Europe, North America, Asia and Oceania).
Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led)
and have a variety of budgets (from being run by volunteers to annual budgets over €200,000). All registries
collect at least some of the originally agreed data items, and a number of additional items have been suggested in
particular items on cognitive impact.
Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes.
Keywords: Myotonic dystrophy, Registries, Clinical trials, Trial readiness
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Background
Patient Registries have the different objectives that include:
[1] improve the understanding of the prevalence, natural
history, pathogenesis, and treatment options of diseases
in recognition by a systematic collection of clinical and
demographic data; [2] set up an infrastructure that allows
collaboration between patients, health and care providers,
academia (research) and industry; and, [3] obtain a picture
of the targeted cohort’s real-life disease burden, standards
of care and patient’s preferences towards treatment [1–3].
In rare diseases such as Myotonic Dystrophy (DM),
Disease-specific Patient Registries have been recognised
as indispensable tools to translate clinical and research
knowledge into therapeutic solutions [1, 4–6]. DM is a
genetically caused neuromuscular condition estimated to
affect 10 per 100,000 people in European populations [7, 8].
It is found in two forms: myotonic dystrophy type 1 (DM1)
and the less frequent myotonic dystrophy type two (DM2).
DM1 is one of the most variable human diseases with a
complex multisystemic presentation. The condition is characterised by progressive muscle wasting and myotonia;
however, it also has significant impact on cognition cardiac,
visual, endocrine, gastrointestinal, and pulmonary systems.
These manifestations have a significant effect impact on
social participation and quality of life [9–13] . There are
currently limited therapies for certain symptoms, and none
to slow down, reverse or cure the disease. As with all rare
diseases, the need to coordinate resources and knowledge
is essential in order to move towards larger and more successful clinical trials and ultimately better management.
The International Rare Diseases Research Consortium
(IRDiRC) advocates for a global collaboration between different disease specific registries collecting a minimum set
of standardised and consistent data that will boost research
at all levels [14]. In 2009, a group of key opinion leaders
agreed upon a minimal core dataset for DM patient registries. This dataset was agreed at a TREAT-NMD/Marigold
workshop held in Naarden, Netherlands and has since been
referred to as the “Naarden” dataset [15, 16]. Since then a
unified global registry for DM, using a federated or centralised model has not been fully established. However, an
increasing number of registries are collecting what was
agreed as essential data on myotonic dystrophy. Here we
present a summary of the global experience of designing
and setting up these registries. We aim to describe the
current landscape of DM registries and to assess how
widely used the Naarden dataset is and its perceived
usefulness or shortcomings.
Methods
Through the platforms of TREAT-NMD (global alliance
with the mission of improving trial readiness in neuromuscular diseases) and the Marigold Foundation (a research foundation DM-specific who commissioned this
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report), 25 registries were identified worldwide and invited to participate (Fig. 1). All registries were invited to
complete an online survey asking about the design, set
up, and utility of the registry. The original data was collection period was between September and December
2015, with updates provided in April 2017. This survey
can be found in the Additional file 1.

Results
Of these 25 registries, 21 were currently active, two had
recently launched and two were still in set up phase.
Twenty-two registries responded to this request, and it
is this information that is described here.
Collectively these registries contain information on over
10,000 DM patients worldwide (Table 1). The longest
standing registry is the “National Registry for Myotonic
Dystrophy and Facioscapulohumeral Muscular Dystrophy
Patients and Family Members” based at the University of
Rochester, USA which started collecting data in 2000 [17].
A further six registries/databases were established before
the publication of the original Naarden dataset (CRAMP,
Genemu, BNMDR and DM-SCOPE and the registries in
Serbia and Bulgaria). In the years since this workshop,
an additional 15 registries collecting data on DM patients
have been launched.
In many cases registries are collecting information on
both DM1 and DM2. Across the registries surveyed, the
majority of records (86%) related to DM1 patients. However, there are some notable exceptions to this only 40%
of patients in the German registry have DM1, and 51%
in ReaDY (Czech Republic). A larger proportion of DM2
patients are also present in Akhenaten (Serbia) and
REMUDY (Japan) where 33% and 20% of registered
patients have DM2.
Mandatory and highly encouraged items

The mandatory and highly encouraged items from the
“Naarden” dataset collected by each registry are summarised in Table 2. All registries collected at least 50%
of the mandatory items as listed in the original core
dataset with 13 (59%) collecting all of these mandatory
items. Eight (36%) registries collected all of the mandatory
and highly encouraged items. Two of the registries set up
before the publication of the Naarden dataset (Genemu
and the Bulgarian registry) already collected all of the
mandatory data items. Ten of the 15 registries launched
after the publication of the Naarden dataset collect all of
these items.
Only 12 (55%) of the 22 registries surveyed asked participants whether they were signed up to another registry to
determine if there are duplicate registrations. Registry
owners were asked which items they would consider removing from the original core dataset, two registry curators answered that ethnic origin was not essential, two
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Fig. 1 Location of registries collecting data on myotonic dystrophy. The countries shaded with stripes are in the set up phase of registries

Table 1 Numbers of patients registered across countries as provided in April 2017
Name of Registry

Country

Year established

DM1 > 18 DM1 < 18 DM2 > 18 DM2 < 18

National Registry for Myotonic Dystrophy and
Facioscapulohumeral Muscular Dystrophy Patients
and Family Members

USA

2000

1177

67

214

0

CRAMPS

Netherlands

2001

452

0

30

0

Genemu**

Quebec, Canada

2005

N/A

N/A

N/A

N/A

Belgian Neuromuscular Disease Registry

Belgium

2008

493

34

16

2

DM-SCOPE

France

2008

2203

255

107

0

Bulgarian Myotonic Dystrophy Registry

Bulgaria

2009

76

2

6

0

2009

335

0

86

0

Akhenaten, Serbian Registry for Myotonic Dystrophies Serbia
Polish Registry of Neuromuscular Patients

Poland

2010

246

7

125

0

ReaDY Myotonic Disorders

Czech Republic

2011

184

5

286

2

Canadian Neuromuscular Disease Registry

Canada

2011

188

21

38

0

New Zealand Neuromuscular Disease Registry

New Zealand

2011

156

11

11

0

Myotonic Dystrophy Patient Registry for Germany
and Switzerland

Germany and Switzerland 2012

243

16

246

3

UK Myotonic Dystrophy Patient Registry

UK

2012

429

45

16

0

China DM Registry

China

2012

61

8

0

0

Spanish Registry of neuromuscular diseases

Spain

2012

265

6

7

0

Egyptian neuromuscular registry

Egypt

2013

4

6

5

3

The Italian registry for Myotonic Dystrophy

Italy

2013

491

16

31

0

Myotonic Dystrophy Family Registry*

USA

2013

1051*

NMiS

Sweden

2013

194

250*
17

0

0

Registry of Muscular Dystrophy REMUDY

Japan

2014

554

45

1

0

Ukrainian registry of muscular dystrophies

Ukraine

Not provided

3

1

0

0

Australian Myotonic Dystrophy Registry***

Australia

Data collection has 0
not yet begun

0

0

0

Totals

9156

Total registered globally

10,641

*Estimates based on literature review. **Recent numbers not available. ***Data collection not yet begun

1485
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Table 2 Proliferation of the core “Naarden” dataset for myotonic dystrophy registries

“X” indicates the item is collected. The highlighted data items those listed as mandatory in the Naarden dataset. The shading indicates that these items are not
collected by the registry

Wood et al. Orphanet Journal of Rare Diseases (2018) 13:155
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suggested the removal of ECG and echocardiogram results
and two suggested that the date and method used for genetic testing should be removed.
Along with the core dataset, many registries collect additional information about myotonic dystrophy patients;
some registries use additional validated questionnaires relating to pain (McGill, BI, NSPI), fatigue (ESS, FDSS) and
quality of life (SF36, InQoL, EQ. 5D and ActivLim). In
addition, some registries collect data regarding the gastrointestinal and central nervous systems and anthropometric measurements. Several registries also include detailed
socioeconomic data. However, there was no standardisation or commonality among these items.

between registries, such as a recent paper from the UK,
Germany and Dutch groups [18].

Purpose and utility of the registries

Resources and technical solutions

The registries and databases contacted were asked to rank
10 possible purposes of registries in order of importance.
The most common purpose was for recruitment into clinical research both for therapeutic and observational studies. Providing feasibility data to researchers and improving
standards of care were also among top priorities. Assessing disease prevalence and analysis of disease progression
were less often the main purpose (Fig. 2).
Thirteen (59%) of the 22 registries reported having
supported recruitment into clinical research, 11 had provided feasibility data for use in planning of a trial and 13
reported entering recruitment of patients to questionnaire
based studies. Eleven (50%) of the registries had contributed to publications in scientific, peer-reviewed journals.
This includes publications resulting from collaborations

Our survey indicated that there is no coordinated or central
funding for DM patient registries. Funding is typically obtained on a national level and is often a combination of
patient organisations or other charitable funding alongside
grant or project funding. One registry receives some
funding from industry (Canadian Neuromuscular Disease
Registry) in addition to other sources, while six (Australia,
BNMDR, China, CRAMP, Egypt, and Italy) receive funds
from the healthcare system or government.
The financial resources required to set up and maintain the registries were not provided in all cases. From
the information available the best-resourced registry is
the Japanese registry of muscular dystrophy (REMUDY)
with set up costs of €420,000; this is followed but the
Canadian Neuromuscular Disease Registry (CNDR with

Registry characteristics

Characteristics of these registries composition are summarised in Table 3.
The majority of the registries surveyed have national
coverage; two (Myotonic Dystrophy Family Registry –
USA and the Egyptian neuromuscular registry) accept
international registrations. Ten (46%) of the registries surveyed are myotonic dystrophy specific while the others are
collecting information on all neuromuscular diseases or a
selection of other conditions (i.e. USA and Poland).

Fig. 2 The registry purpose ranked from most to least importance by registry owners

USA

Netherlands
Quebec

Belgium

France

Serbia
Bulgaria
Poland
Canada

New Zealand

Czech Republic
China
Germany and
Switzerland
Spain

National Registry for Myotonic Dystrophy
and Facioscapulohumeral Muscular Dystrophy
Patients and Family Members (USA)

CRAMPS

Genemu

BNMDR

DM-SCOPE

Akhenaten, Serbian Registry for Myotonic
Dystrophies

Bulgarian Myotonic Dystrophy Registry

Polish Registry of Neuromuscular Patients

Canadian Neuromuscular Disease Registry

New Zealand Neuromuscular Disease Registry

ReaDY Myotonic Disorders

China DM Registry

Myotonic Dystrophy Patient Registry for
Germany and Switzerland

Spanish Registry of neuromuscular diseases

Coverage of
Registry

All Neuromuscular diseases

DM1, DM2

All Neuromuscular diseases

All myotonic disorders

All neuromuscular diseases

All neuromuscular diseases

DM1, DM2, SMA, DMD/BMD

DM1, DM2

DM1, DM2

DM1, DM2

All Neuromuscular diseases

DM1, DM2

All neuromuscular diseases

DM1,DM2,FSHD

Scope of Registry

Grant or project funding

Unknown

Healthcare system

Charity

Charity

Industry, Charity,
Grant or project funding

Project Grant

N/A

Grant or Project funding

Charity

Healthcare system

Grant or Project funding

Healthcare System

Grant or Project funding

Funding Mechanism

Table 3 Configuration and set up of the 22 registries actively collecting data on myotonic dystrophy patients

Paper
Electronic database
Electronic database
(custom solution)
Electronic database
(RDRF)

Electronic database
(Oracle)

€0
€ 200,000

€ 30,000

€10,000

Electronic database

Electronic database
(SQL)

Unknown

€ 50,000

€7500

Electronic database
(Excel)

€0

N/A

€140,000

Electronic database

Electronic database
(healthdata.be)
Paper

€ 145,000

Unknown

Electronic database
N/A

Unknown

Paper
Electronic database
(Access, SAS)

Data collection tool

€23,000

Unknown

Annual running
costs

Clinical specialists

Clinical specialists
General practitioners
Patients

Clinical specialists

Healthcare professional
(nurse, clerk, research
assistant)
Patients

Healthcare professional
(nurse, clerk, research
assistant)

Clinical specialist

Clinical specialists

Clinical specialists

Healthcare professional
(nurse, clerk, research
assistant)
Clinical specialists
Geneticist (diagnostic lab)

Healthcare professional
(nurse, clerk, research
assistant)
Clinical Specialists

Healthcare professional
(nurse, clerk, research
assistant)

Clinical specialists

Healthcare professional
(nurse, clerk, research
assistant)
Patients
Clinical specialists

Who enters the data
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Japan

Australia

Ukraine

Registry of Muscular Dystrophy REMUDY

Australian Myotonic Dystrophy Registry

Ukrainian registry of muscular dystrophies

All inherited myopathies

Sweden
Italy

NMiS

The Italian registry for Myotonic Dystrophy

DM1, DM2

International

Myotonic Dystrophy Family Registry

All neuromuscular diseases

DM1, DM2

All Neuromuscular diseases

DM1, DM2

All Neuromuscular diseases

International

Egyptian neuromuscular registry

DM1, DM2

UK

Scope of Registry

UK Myotonic Dystrophy Patient Registry

Coverage of
Registry

Charity

Government, Hospital and
Clinical groups.

Grant of project funding

Grant or project funding.

Government funding

unknown

Healthcare system

Charity
Grant of project funding

Funding Mechanism

Paper

€200

Electronic database

€ 12,954

Paper
Electronic database
(excel)

Paper
Electronic database
(custom solution)

€420,000

Unknown

Electronic database
Electronic database

€ 10,000
€ 30,000

Electronic database
(patient crossroads)

Electronic database
(custom solution)

€ 15,000

unknown

Data collection tool

Annual running
costs

Table 3 Configuration and set up of the 22 registries actively collecting data on myotonic dystrophy patients (Continued)

Clinical specialists
General practitioners
Patients

Clinical specialists
Healthcare professional
(nurse, clerk, research
assistant)
Geneticist (diagnostic lab)

Patients
Clinical specialists

Patients
Clinical specialists

Clinical specialists

Patients
Family members

Clinical specialists

Healthcare professional
(nurse, clerk, research
assistant)
Patients
Clinical specialists

Who enters the data

Wood et al. Orphanet Journal of Rare Diseases (2018) 13:155
Page 7 of 11

Wood et al. Orphanet Journal of Rare Diseases (2018) 13:155

set up costs of €240,000 ($337,000 CAD) and annual
running costs of €250,000 ($350,000 CAD). Notably both
registries collect information from a range of neuromuscular diseases and these resources are not dedicated to myotonic dystrophy. At the other end of the scale, there is the
Bulgarian Myotonic Dystrophy Registry, which has received
no funding and is managed through free donation of the
team’s time. A number of other registries have received
funding to set up the registry but this has not been sustained and they are now running on limited or no funds.
Not considering these outliers, the mean set up cost was
€53,100 (range €1000 – € 145,000) and the annual running
costs €200 to €145,000 with a mean of €49,711.55.
This diversity in funding is reflected in the data capture methods implemented with no two registries using
the same IT solutions, and some using hard copy data
collection methods. The electronic solutions vary from
excel spreadsheets to complex custom software systems.
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number of socio economic items (insurance coverage,
employment status, income range and marital status) relevant for analysis. These cohorts share challenges with the
more traditional registries in terms of resources to ensure
data quality and governance.

Discussion
Patient Registries are a key concern for all those involved
in the rare diseases field, however only about a fifth of rare
diseases have registries [19]. DM is one of these rare diseases with a clear interest and investment in registries.
These registries represent over 10,000 DM patients which
represents a promising resource to support trial readiness
aims such as feasibility and recruitment and the importance of cross international boundaries in this topic. This
overview presents a summary of the global infrastructure
currently available for DM and highlights points of agreement between different registries and caveats that can be
improved to allow efficient future collaborations.

Data entry

Data is most often updated annually, with most registries
striving for annual updates though some stating this is
not always possible due to resource limitations. A number
of registries (Ukraine and Egypt) update details on a
six-monthly basis.
All but one of the surveyed registries involves data
entry by a clinician or another healthcare professional.
Only the Myotonic Dystrophy Family Registry (USA) is
entirely patient reported. However, an element of patient
reported data is included in seven additional registries
(UK, Italy, and USA National Registry at the University of
Rochester, Japan, Germany, New Zealand and Ukraine).
Several registries (DM-Scope and Australian DM registry)
also allow data entry from the diagnostic laboratory.
Alternative cohorts

Throughout this process it has been acknowledged that
there are many additional cohorts with valuable data on
myotonic dystrophy patients; this includes data being
collected in natural history studies, clinical trials and by
patient organisations and mailing lists. Two of the most
significant of these so-called “alternative” cohorts, are
held by the myotonic dystrophy support group (MDSG)
in the UK and the Muscular Dystrophy Association (MDA)
in the USA. MDSG collects contact details of families
in the UK, this is allows them to provide a quarterly
newsletter and act as a central point for of information
and support. There are currently more than 2500 families
registered with MDSG, this database does not contain clinical or symptomatic details. MDA holds information on
over 10,500 people with a diagnosis of myotonic dystrophy
(DM1 and DM2), the majority of whom are adults. Developed initially as contact databases, these therefore does
not collect the Naarden dataset, however they capture a

Utility and proliferation of the “Naarden Dataset”

Despite the variability seen across registries, in set-up,
purpose and execution many of the items of the original
dataset remain relatively consistent across resources.
The impact can be seen in the number of new registries
(66%) having adopted all of the mandatory items since
2009, compared to the 28% of registries that collected
these items prior to the Naarden workshop. The fact
that there was no agreement on items to be removed or
added suggests that the “Naarden” dataset may still be
an appropriate minimal dataset for myotonic dystrophy
patient registries. It is important to note that there is significant number of registries not yet collecting all items
of the core dataset. This may reflect the variety of resources available to the registries. However, it may also
indicate a need to increase awareness of the dataset and
to better highlight the added value to of collecting this
data in a harmonised way. Yet, with many registries collecting items beyond the previously agreed dataset an
expansion of the dataset could be considered, in particular the addition of anthropometric measurements and
items looking at cognitive impairment. Furthermore, the
higher frequency of DM2 patients in some areas of central Europe may also call for an adapted dataset accounting for differences in phenotypic presentation. With
more patients entering clinical trials over the coming
years, this should be captured in additional questions.
The growing number of registries collecting additional
patient reported outcomes also calls for further consideration. A significant amount of work has already been done
towards the selection and harmonisation of disease-specific
reported outcomes by the Outcome Measures for Myotonic
Dystrophy initiative (OMMYD) [20, 21]. The registry community should consider adopting these guidelines to ensure
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only tools validated in these disease areas are included. We
also recognise the importance of including patient representation when refining the outcomes most appropriate to
include in registries.
The numbers of research studies and publications derived from the registries demonstrate the utility of the
registries. This is best demonstrated in the multicentre
clinical trial setting of OPTIMISTIC [22], in which the registries from the UK, France, Germany and the Netherlands
were successfully used for feasibility and recruitment.
This experience together with tools already developed
by TREAT-NMD mean that the myotonic dystrophy
registry community is well placed to help facilitate and
accelerate clinical research.
Future harmonisation and interoperability

There is a clear need for a more integrated approach to
DM registries; however, the building blocks for increased
collaboration are in place. The registries identified, share
common data items and have the same fundamental
purpose. All of the registries we contacted were open to
the idea of increased collaboration. However, the diversity in registry collection methods may present a bottleneck when looking to future interpretability. As part of a
recent collaboration between three of these registries
surveying about falls and related injuries, minor differences between collected demographic data limited the
full interpretability of the results from the questionnaire
[18]. Within the wider rare disease registry community
there is a call for more standardised collection of data
using ontologies and for data to be meet the FAIR (Findable, accessible, interoperable and reusable) data principles
[23, 24]. Interoperability of these datasets could also be
addressed through a common identifier, or privacy protection record linkage (PPRL). The myotonic dystrophy community is well placed to be part of these developments.
Some investment would be required in order for the
existing registries to meet these standards; however, a
significant amount of work in this area is being carried
out in some larger projects such as RD-Connect [25],
who are looking to demonstrate how different datasets
including registries can be linked. Beyond connecting
registries with each other, increased value could come
from further linking registry data to biobanks, natural
history and omics data for example. Furthermore, these
larger initiatives should be utilised to increase the visibility of these registries, for example, currently a search of
the Orphanet catalogue of rare disease registries listed
only 9 DM registries while the RD-Connect Registry and
Biobank Finder system returns 13 results.
It would be unrealistic to expect that a single individual or group will fully lead the establishment of a global
and unique rare-disease registry. Patient registries are
dependent on the availability of resources (human and
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technology), standards of care and research and specific
regulatory bodies or criteria [1, 4, 26]. However, this report can be considered a rare disease case-study about
the success of collaborating at a global level and the importance of establishing a set of data considered essential for a disease-specific patient registry.

Conclusion
In conclusion, there is a desire within the myotonic dystrophy community to better unite the registry landscape
and increase interoperability. Consideration will have to be
given to the resources available for this to ensure sustainability. In addition, it is important to see how these registries fit in the bigger picture of the rare disease community.
The registries contacted are eager to increase and continue
this collaboration, a follow-up workshop might be required
to work towards meeting the goals of standardisation and
interpretability. Such a workshop could also be used to better address the impact of the data set in the current trial
landscape. The networks provided by TREAT-NMD,
RD-Connect, and the International Rare Diseases Research
Consortium (IRDiRC) represent access to the necessary
tools and stakeholders to ensure the greatest impact of
these valuable resources. The utility could be further demonstrated through analysis of the data within all of these
registries. Analysis on the 10,000 patients would provide an
insight into this condition on a scale not previously seen.
Highlights
 Disease-specific Patient Registries are indispensable

platforms to succeed with therapeutic solutions.
 Over 10,000 myotonic dystrophy patients captured

in registries worldwide.
 Twenty-two registries collect a comparable dataset

on myotonic dystrophy patients.
 There is still a huge variety in data collection and

funding mechanisms among registries.
 Significant clinical research has been supported by

these myotonic dystrophy registries.

Additional file
Additional file 1: Survey to capture details about the registry, database
or mailing list. (PDF 270 kb)
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dystrophy type 1; DM2: Myotonic dystrophy type 2; ECG: Electrocardiogram;
ESS: Epworth Sleepiness Scale; FAIR: Findable Accessible Interoperable and
Reusable; FDSS: Fatigue and Daytime Sleepiness Scale; InQoL: Individualised
Neuromuscular Quality of Life; IRDiRC: International Rare Diseases Research
Consortium; MDA: Muscular Dystrophy Association; MDSG: Myotonic
Dystrophy Support Group; NMiS: Neuromuscular Diseases in Sweden;

Wood et al. Orphanet Journal of Rare Diseases (2018) 13:155

PPRL: Personal protection record linkage; ReaDY: Registry of Muscular
Dystrophy, Czech Republic; REMUDY: Registry of Muscular Dystrophy, Japan;
TREAT-NMD: Translational Research in Europe Assessment and Treatment of
Neuromuscular Diseases
Acknowledgements
The authors would like to acknowledge the Marigold Foundation for funding
this global registry review. Many people and funding bodies have been
involved in the set up and data collection. The Serbian registry for myotonic
dystrophy is supported by a grant from the Ministry of Education, Science
and Technological Development of the Republic of Serbia (grant# 175083).
The CNDR was founded on a generous grant from the Marigold Foundation,
and grants from ALS Canada, Jesse’s Journey, Families of SMA Canada, the
Starratt Family Foundation, Biogen, and Sanofi Genzyme. The National
Registry of Myotonic Dystrophy and FSHD Patients and Family Members at
the University of Rochester is supported through the National Institute of
Neurological Disorders and Stroke (NIH Senator Paul D. Wellstone Muscular
Dystrophy Cooperative Research Center grant #U54-NS048843: PI: Dr. Richard
T. Moxley, III); the Saunders Family Fund; and the Abrams Family Fund for
Myotonic Dystrophy Research. The Italian National Registry for DM was
funded by an Italian Ministry of Health Research Grant and an Intramural
Research Grant from IRCCS Policlinico San Donato. The UK myotonic
dystrophy patient registry has received funding from Muscular Dystrophy UK
(MDUK) and the Myotonic Dystrophy Support Group (MDSG). REMUDY was
supported in part by research grants from the Ministry of Health and Welfare
of Japan (H26-Nachitou (Nan)-Ippan-086, H28-Nachitou (Nan)-Ippan-030) and
Intramural Research Grants for Neurological and Psychiatric Disorders of the
NCNP (26-7, 29-3). The German registry receives funding from the Deutsche
Gesellschaft für Muskelkranke e.V. This work has received funding from the
European Community’s Seventh Framework Programme (FP7/2007-2013)
under grant agreement n° 305444 “RD-CONNECT: An integrated platform
connecting registries, biobanks and clinical bioinformatics for rare disease
research”, Hanns Lochmüller has received funding from the Medical Research
Council UK (grant reference G1002274, grant ID 98482).
Most importantly, the authors would like to thank the patients and families
affected by myotonic dystrophy who have contributed to the registries
discussed here.
Funding
Newcastle University, received funding from the Marigold Foundation to
carry out this work. Individual registry funding has been listed in the
acknowledgments where appropriate.
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
LW was responsible for all data collection, primary analysis and manuscript
draft. HL was principle investigator for this study, developing study plans and
supporting all data collection and analysis. ACJM contributed to primary data
analysis and manuscript drafting. GB, CB, CC, LC,YD, HD, JADM, CD, ReS, BF,
CG, JH, KK, EK, LK, AKP, CL, BL, EL, AL, RM, GM, LO, MPT, SP, JP, VRS, MR, RHR,
BS, SS, AS, ST, IT, BvE and SV all contributed primary data collection. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne,
UK. 2Centre de référence des maladies neuromusculaires, Hôpital Henri

Page 10 of 11

Mondor, Paris, France. 3Scientific Institute of Public Health, Brussels, Belgium.
Western University, London, Canada. 5Centre de recherche du CHU de
Québec, Université Laval, Quebec, Canada. 6Department of Neurology,
Peking Union Medical College Hospital, Chinese Academy of Medical
Sciences, Beijing, China. 7Office of Population Health Genomics, Perth,
Western Australia. 8Neuromuscular disorders Unit, Hospital de la Santa Creu I
Sant Pau, Barcelona, Spain. 9Neuromuscular & Neuro-genetics Unit, Air
Hospital, Cairo, Egypt. 10U.O. Neurology and Stroke Unit, IRCCS Policlinico San
Donato, San Donato Milanese, Milan, Italy. 11Department of Neurology,
University of Rochester Medical Center, Rochester, NY, USA. 12Department of
Neurology, Alexandrovska University Hospital, Medical University, Sofia,
Bulgaria. 13Department of Promoting Clinical Trial and Translational Medicine,
National Center for Neurology and Psychiatry, Translational Medical Center,
Kodaira, Japan. 14University of Calgary, Calgary, Canada. 15Department of
Neurology, Medical University of Warsaw, Warszawa, Poland. 16University
Hospital Örebro, Örebro, Sweden. 17University Hospital Prague- Motol and
Charles University Prague, Prague, Czech Republic. 18Muscular Dystrophy
Association, Chicago, USA. 19Department of Functional Diagnostic Science,
Osaka University Graduate School of Medicine, Suita, Japan. 20Neurology
Clinic, School of Medicine, University of Belgrade, Belgrade, Serbia.
21
Neurology, Auckland City Hospital, Private Bag 92024, Auckland 1142, New
Zealand. 22Friedrich-Baur-Institute, Department of Neurology, Klinikum
München, Munich, Germany. 23Centro de Investigación Biomédica en Red en
Enfermedades Raras (CIBERER), Valencia, Spain. 24Institute of Neurology,
Psychiatry and Narcology, Academy of medical science of Ukraine, Kharkiv,
Ukraine. 25Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands. 26University Hospital and Masaryk University Brno, Brno, Czech
Republic. 27Department of Neuropediatrics and Muscle Disorders, Medical
Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
28
Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic
Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona,
Spain.
4

Received: 27 February 2018 Accepted: 12 August 2018

References
1. Lacaze P, Millis N, Fookes M, Zurynski Y, Jaffe A, Bellgard M, et al. Rare
disease registries: a call to action. Intern Med J. 2017;47(9):1075–9.
2. Mehta A. The how (and why) of disease registers. Early Hum Dev. 2010;
86(11):723–8.
3. Europe ERD. EURORDIS' Position on rare disease researcg 2010 [Available
from: https://www.eurodis.org/sites/default/files/EURORDIS_Rapport_
Research_2012.pdf. Accessed 28 July 2018.
4. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rarediseases registry. Lancet. 2011;377(9771):1057–9.
5. Jaffe A, Zurynski Y, Beville L, Elliott E. Call for a national plan for rare
diseases. J Paediatr Child Health. 2010;46(1–2):2–4.
6. Butcher J. Cooperation is key, say neuromuscular-disease researchers. Lancet
Neurol. 2007;6(4):298–9.
7. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V.
Prevalence of genetic muscle disease in northern England: in-depth analysis
of a muscle clinic population. Brain J Neurol. 2009;132(Pt 11):3175–86.
8. Harper PS. Myotonic dystrophy. 3WB Saunders. London, UKrd edn 2001.
9. Peric S, Stojanovic VR, Basta I, Peric M, Milicev M, Pavlovic S, et al. Influence
of multisystemic affection on health-related quality of life in patients with
myotonic dystrophy type 1. Clin Neurol Neurosurg. 2013;115(3):270–5.
10. Antonini G, Soscia F, Giubilei F, De Carolis A, Gragnani F, Morino S, et al.
Health-related quality of life in myotonic dystrophy type 1 and its
relationship with cognitive and emotional functioning. J Rehabil Med. 2006;
38(3):181–5.
11. Gagnon C, Mathieu J, Noreau L. Life habits in myotonic dystrophy type 1. J
Rehabil Med. 2007;39(7):560–6.
12. Hermans MC, Merkies IS, Laberge L, Blom EW, Tennant A, Faber CG. Fatigue
and daytime sleepiness scale in myotonic dystrophy type 1. Muscle Nerve.
2013;47(1):89–95.
13. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.
Electrocardiographic abnormalities and sudden death in myotonic
dystrophy type 1. N Engl J Med. 2008;358(25):2688–97.
14. EURORDUS-NORD-CORD. Joint Declaration of 10 Key Principles for Rare
Disease Patients Registries 2012 [Available from: http://download.eurordis.

Wood et al. Orphanet Journal of Rare Diseases (2018) 13:155

15.

16.
17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

org/documents/pdf/EURORDIS_NORD_CORD_JointDec_Registries_FINAL.
pdf. Accessed 28 July 2018.
Thompson R, Schoser B, Monckton DG, Blonsky K, Lochmuller H. Patient
Registries and Trial Readiness in Myotonic Dystrophy--TREAT-NMD/Marigold
International Workshop Report. Neuromuscular disorders: NMD. 19. England
2009. p. 860–866.
Bushby K, Lynn S, Straub T. Collaborating to bring new therapies to the
patient--the TREAT-NMD model. Acta Myol. 2009;28(1):12–5.
Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, et
al. If you build a rare disease registry, will they enroll and will they use it?
Methods and data from the National Registry of myotonic dystrophy (DM)
and Facioscapulohumeral muscular dystrophy (FSHD). Contemporary clinical
trials. 2012;33(2):302–11.
Jimenez-Moreno AC, Raaphorst J, Babačić H, Wood L, van Engelen B,
Lochmüller H, et al. Falls and resulting fractures in myotonic dystrophy:
results from a multinational retrospective survey. Neuromuscul Disord. 2017;
Wrobel P. Workshop on patients registries for rare disorders: need for data
collection to increase knowledge on rare disorders and optimize disease
management and care. Paris, France 2013 [Available from: http://www.
eucerd.eu/wp-content/uploads/2013/06/WP8WorkshopEJAEPIRARE.pdf.
Accessed 28 July 2018.
Gagnon C, Meola G, Hebert LJ, Laberge L, Leone M, Heatwole C. Report of
the second outcome measures in myotonic dystrophy type 1 (OMMYD-2)
international workshop san Sebastian, Spain, October 16, 2013.
Neuromuscular disorders: NMD. 2015;25(7):603–16.
Gagnon C, Meola G, Hebert LJ, Puymirat J, Laberge L, Leone M. Report of
the first outcome measures in myotonic dystrophy type 1 (OMMYD-1)
international workshop: Clearwater, Florida, November 30, 2011.
Neuromuscular disorders: NMD. 2013;23(12):1056–68.
van Engelen B. Cognitive behaviour therapy plus aerobic exercise training
to increase activity in patients with myotonic dystrophy type 1 (DM1)
compared to usual care (OPTIMISTIC): study protocol for randomised
controlled trial. Trials. 2015;16:224.
Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A,
et al. The FAIR guiding principles for scientific data management and
stewardship. Scientific data. 2016;3:160018.
Kohler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I, et al.
The human phenotype ontology project: linking molecular biology and
disease through phenotype data. Nucleic Acids Res. 2014;42(Database
issue):D966–74.
Thompson R, Johnston L, Taruscio D, Monaco L, Beroud C, Gut IG, et al. RDConnect: an integrated platform connecting databases, registries, biobanks
and clinical bioinformatics for rare disease research. J Gen Intern Med. 2014;
29(Suppl 3):S780–7.
Bellgard M, Beroud C, Parkinson K, Harris T, Ayme S, Baynam G, et al.
Dispelling myths about rare disease registry system development. Source
code for biology and medicine. 2013;8(1):21.

Page 11 of 11

